Keymed Biosciences
Beyond's analysis on Keymed Biosciences
- — Keymed Biosciences reports H1 2026 revenue of 617 million RMB, driven by its Kangyueda product
- — Keymed Biosciences reports H1 2026 revenue of 617 million RMB driven by core product Kangyueda
- — Keymed Biosciences reports H1 2026 revenue of 617 million RMB, driven by flagship Kangyueda sales
- — Keymed Biosciences posts strong H1 2026 growth, with core product Kangyueda sales up 132% YoY, underscoring momentum in China's biotech sector
Recent news mentioning Keymed Biosciences
- — Keymed Biosciences anuncia los resultados del primer semestre de 2026 y novedades empresariales
- — Keymed Biosciences gibt Ergebnisse für das erste Halbjahr 2026 sowie aktuelle Geschäftsentwicklungen bekannt
- — Keymed Biosciences annonce ses résultats pour le premier semestre 2026 et fait le point sur ses activités
- — Keymed Biosciences Announces 2026 H1 Results and Business Updates
- — Keymed Biosciences Announces 2026 H1 Results and Business Updates